Development of totally implantable pulsatile biventricular assist device.

Institute of Medical and Biological Engineering, Medical Research Center, Seoul National University, Korea.
Artificial Organs (Impact Factor: 1.87). 02/2003; 27(1):119-23. DOI: 10.1046/j.1525-1594.2003.07177.x
Source: PubMed

ABSTRACT Approximately 10% to 15% of all patients implanted with left ventricular assist devices (LVADs) have required right heart support with another device. The necessity of aggressive biventricular support has already been proposed. Therefore, the totally implantable biventricular assist device (BVAD) was developed. The width of the BVAD main body was 87 mm, the thickness 67 mm, and the height 106 mm, while the weight was 785 g. The automatic control algorithm was developed to prevent lung edema and atrial rupture.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The complexity of the brain and the membranous blood-brain barrier (BBB) has proved to be a significant limitation to the systemic delivery of pharmaceuticals to the brain rendering them sub-therapeutic and ineffective in the treatment of neurological diseases. Apart from this, lack of innovation in product development to counteract the problem is also a major contributing factor to a poor therapeutic outcome. Various innovative strategies show potential in treating some of the neurological disorders; however drug delivery remains the most popular. To attain therapeutic drug levels in the central nervous system (CNS), large, intolerable systemic doses are generally administered. The success of maintenance therapy in many neurological diseases depends on a number of variables, including the constant release of neurotherapeutics, a reduction in the dosing frequency, a greater antipsychotic drug bioavailability and ultimately improved patient compliance, many of which is not achievable by conventional oral or parenteral formulations. This article reviews the therapeutic implantable polymeric and transdermal devices employed in an attempt to effectively achieve therapeutic quantities of drug across the BBB over a prolonged period, to improve patient disease prognosis.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic Artificial Organs (TAO) are extracorporeal life-saving devices that are used to bridge patients from emergency to surgery and recovery. This paper details the research on TAOs in Korea along with their development as the clinical devices. In the heart and lung area, the artificial heart system (AnyHeart) and the pulsatile heart-lung machine (T-PLS) have been developed. The T-PLS has been used in 400 patients. In the renal replacement area, the portable hemofiltration machine (C-PAK) and its applications in home renal treatment are currently being tested through animal experiments. The multiple applications of the biomaterials, the electromechanical system designs and their control, the telecommunication technology and medical technology have been combined in the research and development of life-saving artificial organs for critically ill patients.
    International Journal of Applied Electromagnetics and Mechanics 01/2008; 27:205-214. · 0.74 Impact Factor
  • Artificial Organs 07/2013; 37(7):587-90. · 1.87 Impact Factor

Full-text (2 Sources)

Available from
May 30, 2014